HCMR Re-Imaging Study

NCT07054073 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2026-03-18

No results posted yet for this study

Summary

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system.

This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

OTHER

None - observational study

None - observational study

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER
  • Mayo Clinic

    collaborator OTHER
  • Tufts Medical Center

    collaborator OTHER
  • Northwestern University

    collaborator OTHER
  • University of Michigan

    collaborator OTHER
  • The Cleveland Clinic

    collaborator OTHER
  • University Hospital Birmingham NHS Foundation Trust

    collaborator OTHER
  • Glenfield Hospital, Leicester

    collaborator OTHER
  • London Chest Hospital

    collaborator UNKNOWN
  • Cytokinetics

    collaborator INDUSTRY
  • Toronto General Hospital

    collaborator OTHER
  • Christopher Kramer

    lead OTHER

Principal Investigators

  • Christopher Kramer, MD · University of Virginia

  • Stefan Neubauer, MD · University of Oxford

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-03-31
Completion
2027-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054073 on ClinicalTrials.gov